-
Synthetic Biology, Genomics & Advanced Therapeutics6 months ago
Electrorheoimaging Helps Manage Droplet Viscosity in Real-Time
Electrorheoimaging Helps Manage Droplet Viscosity in Real-Time
-
Synthetic Biology, Genomics & Advanced Therapeutics6 months ago
HDX-MS Plus Computational Methods Provide Novel Approach to Study of Protein-Protein Interactions
HDX-MS Plus Computational Methods Provide Novel Approach to Study of Protein-Protein Interactions
-
Synthetic Biology, Genomics & Advanced Therapeutics6 months ago
Benchtop Bioreactor Simplifies Macrophage Manufacturing
Benchtop Bioreactor Simplifies Macrophage Manufacturing
-
Synthetic Biology, Genomics & Advanced Therapeutics6 months ago
CAR T Production Bottlenecks Best Tackled with AI, Automation, and Skilled Staff
CAR T Production Bottlenecks Best Tackled with AI, Automation, and Skilled Staff
-
Uncategorized6 months agoRead the latest issue of DDW
The new issue of DDW is now on its way to subscribers and available to read online. The Spring issue explores the next phase of obesity medications...
-
BioPharma Dive – AI / Data6 months agoAspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection
Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.
-
BioPharma Dive – AI / Data6 months agoCrossbow raises $77M for new cancer immunotherapies
Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead program CBX-250.
-
Fierce Biotech6 months ago
Avoiding 11th hour surprises in clinical trials
Proactive coordination is essential to protect patients, sponsors and trial integrity, especially as teams navigate the new UK Clinical Trial Regulation. Hear why alignment matters more...
-
Nature Biotechnology6 months ago
An engineered E. coli strain sustains intratumoral nitric oxide production to boost effectiveness of tumor immunotherapy
Nature Biotechnology, Published online: 18 March 2026; doi:10.1038/s41587-026-03055-x An engineered Escherichia coli Nissle 1917 strain carrying a synthetic arginine–nitric oxide (NO) circuit enables sustained intratumoral NO...
-
Nature Biotechnology6 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
Nature Biotechnology, Published online: 18 March 2026; doi:10.1038/s41587-026-03054-y Solid tumors are sensitized to anti‑PD‑L1 immunotherapy by engineered E. coli to produce nitric oxide.
FDA clears first generic radioligand drug; Sionna turns to layoffs
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
Ensuring safety and accountability in China’s biomedical translation system
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
